Elevated GALNT10 Expression Identifies Immunosuppressive Microenvironment and Dismal Prognosis of Patients with High Grade Serous Ovarian Cancer

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2019 Dec 20

PMID 31853576

Citations 18

Authors

Guodong Zhang

Jiaqi Lu

Moran Yang

Yiying Wang

Haiou Liu

Congjian Xu

Affiliations

Soon will be listed here.

Abstract

High grade ovarian serous cancer (HGSC) is a malignant disease with high mortality. Glycosylation plays important roles in tumor invasion and immune evasion, but its effect on the immune microenvironment of HGSC remains unclear. This study examined the association of glycosyltransferase expression with HGSC prognosis and explored the underlying mechanism using clinical specimens and integrated bioinformatic analyses. We identified a cluster of 15 glycogenes associated with reduced overall survival, and GALNT10 was found to be an independent predictor of HGSC prognosis. The high GALNT10 expression was associated with increased regulatory CD4+ T cells infiltration and decreased granzyme B expression in CD8+ T cells. The expression of GALNT10 and its product, Tn antigen, in HGSC specimens was associated with the increased infiltration of M2 macrophages and neutrophils, and the decreased infiltration of CD3+ T cells, NK cells, and B cells. Taken collectively, high GALNT10 expression confers with immunosuppressive microenvironment to promote tumor progression and predicts poor clinical outcomes in HGSC patients.

Citing Articles

Integrated multiomics characterization reveals cuproptosis-related hub genes for predicting the prognosis and clinical efficacy of ovarian cancer.

Xiaorong Y, Lu X, Fangyue X, Chao X, Jun G, Qiang W Front Immunol. 2024; 15:1452294.

PMID: 39600695 PMC: 11588705. DOI: 10.3389/fimmu.2024.1452294.

Sex differences and immune correlates of Long COVID development, persistence, and resolution.

Hamlin R, Pienkos S, Chan L, Stabile M, Pinedo K, Rao M bioRxiv. 2024; .

PMID: 38948732 PMC: 11212991. DOI: 10.1101/2024.06.18.599612.

Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer.

Liu Y, Liu S, Yan L, Zhang Q, Liu W, Huang X Mediators Inflamm. 2023; 2023:1400267.

PMID: 38022687 PMC: 10661868. DOI: 10.1155/2023/1400267.

Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.

Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M Mol Cancer. 2023; 22(1):172.

PMID: 37853437 PMC: 10583419. DOI: 10.1186/s12943-023-01877-w.

AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer.

Ardizzoia A, Jemma A, Redaelli S, Silva M, Bentivegna A, Lavitrano M Int J Mol Sci. 2023; 24(14).

PMID: 37511212 PMC: 10380391. DOI: 10.3390/ijms241411455.

References

Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T . The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology. 2012; 23(2):178-87. DOI: 10.1093/glycob/cws139. View

Freire T, Lo-Man R, Bay S, Leclerc C . Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem. 2011; 286(10):7797-7811. PMC: 3048667. DOI: 10.1074/jbc.M110.209742. View

Hanson R, Hollingsworth M . Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling). Biomolecules. 2016; 6(3). PMC: 5039420. DOI: 10.3390/biom6030034. View

Javadi S, Ganeshan D, Qayyum A, Iyer R, Bhosale P . Ovarian Cancer, the Revised FIGO Staging System, and the Role of Imaging. AJR Am J Roentgenol. 2016; 206(6):1351-60. DOI: 10.2214/AJR.15.15199. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Hurt B, Schulick R, Edil B, El Kasmi K, Barnett Jr C . Cancer-promoting mechanisms of tumor-associated neutrophils. Am J Surg. 2017; 214(5):938-944. DOI: 10.1016/j.amjsurg.2017.08.003. View

Schultz M, Swindall A, Bellis S . Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev. 2012; 31(3-4):501-18. PMC: 4079276. DOI: 10.1007/s10555-012-9359-7. View

Fucikova J, Rakova J, Hensler M, Kasikova L, Belicova L, Hladikova K . TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clin Cancer Res. 2019; 25(15):4820-4831. DOI: 10.1158/1078-0432.CCR-18-4175. View

Wu Q, Yang L, Liu H, Zhang W, Le X, Xu J . Elevated Expression of N-Acetylgalactosaminyltransferase 10 Predicts Poor Survival and Early Recurrence of Patients with Clear-Cell Renal Cell Carcinoma. Ann Surg Oncol. 2014; 22(7):2446-53. DOI: 10.1245/s10434-014-4236-y. View

10.

Whiteside T . FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity. Expert Opin Ther Targets. 2018; 22(4):353-363. PMC: 6126897. DOI: 10.1080/14728222.2018.1451514. View

11.

Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y . Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. HLA. 2016; 88(6):275-286. DOI: 10.1111/tan.12900. View

12.

Rodrigues J, Balmana M, Macedo J, Pocas J, Fernandes A, De-Freitas-Junior J . Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. Cell Immunol. 2018; 333:46-57. DOI: 10.1016/j.cellimm.2018.03.007. View

13.

Noy R, Pollard J . Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41(1):49-61. PMC: 4137410. DOI: 10.1016/j.immuni.2014.06.010. View

14.

Sheta R, Bachvarova M, Plante M, Gregoire J, Renaud M, Sebastianelli A . Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer. Int J Oncol. 2017; 51(6):1887-1897. DOI: 10.3892/ijo.2017.4147. View

15.

Suzuki Y, Sutoh M, Hatakeyama S, Mori K, Yamamoto H, Koie T . MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int J Oncol. 2012; 40(6):1831-8. PMC: 3396290. DOI: 10.3892/ijo.2012.1411. View

16.

Oliveira-Ferrer L, Legler K, Milde-Langosch K . Role of protein glycosylation in cancer metastasis. Semin Cancer Biol. 2017; 44:141-152. DOI: 10.1016/j.semcancer.2017.03.002. View

17.

Carrascal M, Severino P, Cabral M, Silva M, Ferreira J, Calais F . Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol. 2014; 8(3):753-65. PMC: 5528624. DOI: 10.1016/j.molonc.2014.02.008. View

18.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

19.

Dahmani A, Delisle J . TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. Cancers (Basel). 2018; 10(6). PMC: 6025055. DOI: 10.3390/cancers10060194. View

20.

Langbecker D, Janda M . Systematic review of interventions to improve the provision of information for adults with primary brain tumors and their caregivers. Front Oncol. 2015; 5:1. PMC: 4304357. DOI: 10.3389/fonc.2015.00001. View